Brokerage firm HSBC Upgrades its rating on Qiagen NV(NASDAQ:QGEN). The shares have been rated Buy. Previously, the analysts had a Hold rating on the shares. The rating by HSBC was issued on Aug 1, 2016.
Qiagen NV (QGEN) shares turned negative on Mondays trading session with the shares closing down -0.39 points or -1.45% at a volume of 9,55,920. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $26.87. The peak price level was also seen at $26.87 while the days lowest was $26.52. Finally the shares closed at $26.56. The 52-week high of the shares is $28.53 while the 52-week low is $19.94. According to the latest information available, the market cap of the company is $6,215 M.
Qiagen NV(QGEN) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $334.40M. Analysts had an estimated revenue of $326.73M. Earnings per share were $0.24. Analysts had estimated an EPS of $0.23.
QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products as well as instruments that automate the use of these products for sample preparation analysis and interpretation. The Company’s bioinformatics solutions connect laboratory workflows and process amounts of genomic data enabling scientists or clinicians to interpret results and decide on further action.